Published in Onco Targets Ther on June 26, 2013
The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis. Cell Cycle (2014) 0.94
Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer. J Transl Med (2015) 0.83
Cell polarity signaling in the plasticity of cancer cell invasiveness. Oncotarget (2016) 0.82
Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas. Oncotarget (2015) 0.79
Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges. Trends Cancer (2017) 0.77
Pragmatic medicine in solid cancer: a translational alternative to precision medicine. Onco Targets Ther (2016) 0.75
ARHGAP42 is activated by Src-mediated tyrosine phosphorylation to promote cell motility. J Cell Sci (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM THE TUMOR CELLS. J Exp Med (1911) 29.44
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov (2004) 15.57
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature (1976) 9.81
Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol (2006) 8.81
Modeling tissue morphogenesis and cancer in 3D. Cell (2007) 7.49
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med (2011) 6.21
The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol (2012) 6.07
Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov (2012) 5.55
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med (2011) 5.54
Raising the bar for cancer therapy models. Nat Biotechnol (2010) 4.52
Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev (2009) 4.36
Chemotaxis in cancer. Nat Rev Cancer (2011) 3.68
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol (2011) 3.58
The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer (2011) 3.42
The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov (2011) 3.42
Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta (2002) 3.33
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell (2012) 3.19
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol (2010) 3.15
Deconstructing the third dimension: how 3D culture microenvironments alter cellular cues. J Cell Sci (2012) 2.89
Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell (2011) 2.77
Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer (2011) 2.42
E-cadherin-integrin crosstalk in cancer invasion and metastasis. J Cell Sci (2013) 2.23
Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer (2008) 2.21
Advances in the preclinical testing of cancer therapeutic hypotheses. Nat Rev Drug Discov (2011) 2.19
Directed cell invasion and migration during metastasis. Curr Opin Cell Biol (2011) 2.12
Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett (2012) 2.07
Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer (2009) 2.06
EMT is the dominant program in human colon cancer. BMC Med Genomics (2011) 2.05
The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol (2010) 1.96
Assessing tumor response to therapy. J Nucl Med (2009) 1.95
Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology (2010) 1.81
Invadopodia: at the cutting edge of tumour invasion. J Clin Neurosci (2008) 1.77
Development of novel combination therapies. N Engl J Med (2011) 1.74
Two hundred years of cancer research. N Engl J Med (2012) 1.69
Pericytes: gatekeepers in tumour cell metastasis? J Mol Med (Berl) (2007) 1.69
Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst (2006) 1.63
Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov (2012) 1.61
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol (2009) 1.61
Cancer metastasis as a therapeutic target. Eur J Cancer (2010) 1.60
Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-p130Cas complex. J Cell Biol (2012) 1.59
SRC: a century of science brought to the clinic. Neoplasia (2010) 1.58
Cell-matrix adhesions in 3D. Matrix Biol (2011) 1.54
The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cell Mol Life Sci (2009) 1.52
The road to Src. Oncogene (2004) 1.51
History of science. Is science mostly driven by ideas or by tools? Science (2012) 1.47
A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res (2007) 1.45
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci (2011) 1.45
Invadosome regulation by adhesion signaling. Curr Opin Cell Biol (2011) 1.38
Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer (2009) 1.38
Mouse modeling in oncologic preclinical and translational research. Clin Cancer Res (2006) 1.35
Case histories, magic bullets and the state of drug discovery. Nat Rev Drug Discov (2006) 1.35
Contractile forces in tumor cell migration. Eur J Cell Biol (2008) 1.31
Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol (2006) 1.30
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
The role of the tissue microenvironment in the regulation of cancer cell motility and invasion. Cell Commun Signal (2010) 1.27
Invadosomes: intriguing structures with promise. Eur J Cell Biol (2011) 1.25
100 years of Rous sarcoma virus. J Exp Med (2011) 1.24
Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts. Korean J Radiol (2012) 1.24
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther (2008) 1.23
Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. Transl Oncol (2012) 1.21
Physico-mechanical aspects of extracellular matrix influences on tumorigenic behaviors. Semin Cancer Biol (2010) 1.21
Current status of SRC inhibitors in solid tumor malignancies. Oncologist (2011) 1.18
The microenvironment determines the breast cancer cells' phenotype: organization of MCF7 cells in 3D cultures. BMC Cancer (2010) 1.16
Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res (2012) 1.14
Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev (2009) 1.14
The history of tumor virology. Cancer Res (2008) 1.14
Biology-driven cancer drug development: back to the future. BMC Biol (2010) 1.12
Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab (2009) 1.11
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function. J Cancer Sci Ther (2009) 1.11
Accelerating identification and regulatory approval of investigational cancer drugs. JAMA (2011) 1.10
Concepts of metastasis in flux: the stromal progression model. Semin Cancer Biol (2012) 1.10
Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem (2004) 1.10
Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer. Ann Oncol (1998) 1.09
Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol (2008) 1.08
Novel oncologic drugs: what they do and how they affect images. Radiographics (2011) 1.05
The structure of invadopodia in a complex 3D environment. Eur J Cell Biol (2010) 1.05
Why does cancer therapy lack effective anti-metastasis drugs? Cancer Lett (2012) 1.03
Primary human tumor xenografted models ('tumorgrafts') for good management of patients with cancer. Anticancer Drugs (2011) 1.03
SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol Cancer Ther (2010) 1.02
Pathological roles of invadopodia in cancer invasion and metastasis. Eur J Cell Biol (2012) 1.01
Src kinase inhibitors: promising cancer therapeutics? Crit Rev Oncog (2012) 1.01
Critical review: cellular mechanobiology and amoeboid migration. Integr Biol (Camb) (2010) 0.97
Tumour-microenvironmental interactions: paths to progression and targets for treatment. Semin Cancer Biol (2010) 0.97
Roles for crk in cancer metastasis and invasion. Genes Cancer (2012) 0.96
What do, can and should we learn from models to evaluate potential anticancer agents? Future Oncol (2006) 0.95
The use of tumour volumetrics to assess response to therapy in anticancer clinical trials. Br J Clin Pharmacol (2012) 0.93
Trastuzumab resistance: all roads lead to SRC. Nat Med (2011) 0.93
Paul Ehrlich: magister mundi. Nat Rev Drug Discov (2004) 0.92
Harnessing genetically engineered mouse models for preclinical testing. Chem Biol Interact (2007) 0.91
Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer. Am J Cancer Res (2012) 0.89
Optimizing a 3D Culture System to Study the Interaction between Epithelial Breast Cancer and Its Surrounding Fibroblasts. J Cancer (2011) 0.88
Tumour invasion and metastasis: challenges facing drug discovery. Curr Opin Pharmacol (2005) 0.88
In vivo/ex vivo and in situ assays used in cancer research: a brief review. Toxicol Pathol (2008) 0.88
Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point? Cancer J (2009) 0.87
Focal adhesion kinase signaling activities and their implications in the control of cell survival and motility. Front Biosci (2003) 2.52
Global impact of oncogenic Src on a phosphotyrosine proteome. J Proteome Res (2008) 1.94
The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cell Mol Life Sci (2009) 1.52
Regulation and localization of CAS substrate domain tyrosine phosphorylation. Cell Signal (2004) 1.47
Contractile forces in tumor cell migration. Eur J Cell Biol (2008) 1.31
The role of the tissue microenvironment in the regulation of cancer cell motility and invasion. Cell Commun Signal (2010) 1.27
Up-regulation of Rho/ROCK signaling in sarcoma cells drives invasion and increased generation of protrusive forces. Mol Cancer Res (2008) 1.14
The structure of invadopodia in a complex 3D environment. Eur J Cell Biol (2010) 1.05
Limits to Precision Cancer Medicine. N Engl J Med (2017) 0.95
Evidence for protein 4.1B acting as a metastasis suppressor. J Cell Sci (2007) 0.94
Invasive cells in animals and plants: searching for LECA machineries in later eukaryotic life. Biol Direct (2013) 0.92
Tyrosine phosphorylation within the SH3 domain regulates CAS subcellular localization, cell migration, and invasiveness. Mol Biol Cell (2011) 0.90
New tools for cancer chemotherapy: computational assistance for tailoring treatments. Mol Cancer Ther (2003) 0.88
ROCK inhibitors as emerging therapeutic candidates for sarcomas. Curr Cancer Drug Targets (2010) 0.88
CAS directly interacts with vinculin to control mechanosensing and focal adhesion dynamics. Cell Mol Life Sci (2013) 0.86
Cytostatic anticancer drug development. J Exp Ther Oncol (2004) 0.84
Human allogeneic keratinocytes cultured on acellular xenodermis: the use in healing of burns and other skin defects. Biomed Mater Eng (2006) 0.83
SH3 domain tyrosine phosphorylation--sites, role and evolution. PLoS One (2012) 0.83
Metastasis of aggressive amoeboid sarcoma cells is dependent on Rho/ROCK/MLC signaling. Cell Commun Signal (2013) 0.83
Neoplastic progression of the human breast cancer cell line G3S1 is associated with elevation of cytoskeletal dynamics and upregulation of MT1-MMP. Int J Oncol (2010) 0.82
NG2-mediated Rho activation promotes amoeboid invasiveness of cancer cells. Eur J Cell Biol (2012) 0.79
Hepatic arterial administration of activated leukocytes in patients with liver metastases. Cancer Biother Radiopharm (2002) 0.78
Urinary neopterin in patients with liver tumors. Tumori (2006) 0.76
Affordable cancer care. Lancet Oncol (2012) 0.76
Prediction of cancer outcome with microarrays. Lancet (2005) 0.75
Posterior capsular opacification with hydrogel, polymethylmethacrylate, and silicone intraocular lenses: two-year results of a randomized prospective trial. Am J Ophthalmol (2002) 0.75
Correcting Hatch-Waxman. Health Aff (Millwood) (2008) 0.75
Haemoglobin concentrations in chronic kidney disease. Lancet (2007) 0.75
Corrigendum: Flow cytometry may allow microscope-independent detection of holocentric chromosomes in plants. Sci Rep (2017) 0.75
Confocal microscopy reveals Myzitiras and Vthela morphotypes as new signatures of malignancy progression. Scanning (2009) 0.75